AlphaCentric Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

AlphaCentric Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-165,000	Closed	-$876K	–	230
2023 Q3	$876K	Sell	165,000 -127,500	-44%	-$1.08M	0.5%	71
2023 Q2	$2.79M	Buy	292,500 +102,500	+54%	+$1.14M	1.55%	11
2023 Q1	$2.09M	Buy	190,000 +111,500	+142%	+$1.61M	1.44%	15
2022 Q4	$1.16M	Buy	+78,500	New	+$1.37M	1.15%	25
2021 Q4	$1.09M	Buy	52,500 +17,000	+48%	+$338K	0.32%	29
2021 Q3	$848K	Buy	35,500 +22,000	+163%	+$502K	0.22%	40
2021 Q2	$368K	Buy	13,500 +1,500	+13%	+$42.3K	0.1%	79
2021 Q1	$347K	Buy	+12,000	New	+$375K	0.12%	70

Other funds holding ARQT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

AlphaCentric Advisors's ARQT Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 165,000 shares — an estimated $876K sold.

AlphaCentric Advisors first reported a position in ARQT in Q1 2021 and held it in 8 quarters. The position peaked at $2.79M in Q2 2023. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

AlphaCentric Advisors reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 165,000 Arcutis Biotherapeutics shares in Q4 2023, an estimated $876K.
AlphaCentric Advisors first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 8 quarters.
AlphaCentric Advisors's Arcutis Biotherapeutics position peaked at $2.79M in Q2 2023.
133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.